Medical Policy Update
November 14, 2018- Botulinum Toxin (BT)
- Cardiovascular Magnetic Resonance (CMR)
- Computed Tomographic Angiography (CTA) and Magnetic Resonance Angiography (MRA) of the Head, Neck, Abdomen, Pelvis, and Lower Extremities
- Electromyography (EMG), Nerve Conduction Studies (NCS), and Other Electrodiagnostic (EDX) Related Services
- Hepatitis C First Generation Agents – Through Preferred Agent
- Hepatitis C Second Generation Antivirals – Through Preferred Agent(s)
- Influenza Virus Diagnostic Testing and Treatment in the Outpatient Setting
- Injectable Atopic Dermatitis Agent(s)
- Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
- Insomnia Agents (Sherwood Employer Group)
- Intensity Modulated Radiotherapy (IMRT)
- Monitored Anesthesia Care
- Multigene Expression Assay for Predicting Recurrence in Colon Cancer
- Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA
- Ocaliva (obeticholic acid)
- Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
- Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (VUR)
- Positron Emission Tomography (PET) Scanning: Oncologic Applications
- Posterior Tibial Nerve Stimulation
- Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)
- Soliris® (eculizumab)
- Statin Therapy
- Testing for Vitamin D Deficiency
- Total Artificial Hearts and Ventricular Assist Devices
- Xermelo (telotristat)
Source: https://www.bcbsks.com/CustomerService/Providers/MedicalPolicies/policies.shtml